# Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD)

> **NCT04882228** · PHASE4 · UNKNOWN · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 278 (estimated)

## Conditions studied

- Chronic Venous Disease

## Interventions

- **DRUG:** Entelon Tab.150mg
- **DRUG:** Venitol Tab.
- **DRUG:** Placebo of Venitol Tab.
- **DRUG:** Placebo of Entelon Tab.150mg

## Key facts

- **NCT ID:** NCT04882228
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-28
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 278 (ESTIMATED)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04882228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04882228, "Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04882228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*